Ignite Creation Date:
2024-05-06 @ 4:08 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04889118
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-09
First Post:
2021-05-12
Brief Title:
Safety and Efficacy Study of Pembrolizumab MK-3475 Combined With Lenvatinib MK-7902E7080 as First-line Intervention in Adults With Advanced Melanoma MK-7902-003E7080-G000-312LEAP-003-China Extension Study
Sponsor:
Organization:
Merck Sharp Dohme LLC